1. Home
  2. NICE vs BLCO Comparison

NICE vs BLCO Comparison

Compare NICE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NICE Ltd

NICE

NICE Ltd

N/A

Current Price

$116.94

Market Cap

5.6B

Sector

Technology

ML Signal

N/A

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

N/A

Current Price

$17.35

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NICE
BLCO
Founded
1986
1853
Country
Israel
Canada
Employees
N/A
13000
Industry
Computer Software: Prepackaged Software
Ophthalmic Goods
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.1B
IPO Year
1999
2022

Fundamental Metrics

Financial Performance
Metric
NICE
BLCO
Price
$116.94
$17.35
Analyst Decision
Buy
Buy
Analyst Count
14
15
Target Price
★ $132.77
$19.39
AVG Volume (30 Days)
★ 504.4K
308.9K
Earning Date
11-12-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $5,101,000,000.00
Revenue This Year
$8.03
$7.68
Revenue Next Year
$9.06
$5.95
P/E Ratio
$11.21
★ N/A
Revenue Growth
N/A
★ 6.47
52 Week Low
$83.10
$14.32
52 Week High
$138.58
$18.92

Technical Indicators

Market Signals
Indicator
NICE
BLCO
Relative Strength Index (RSI) 59.96 53.96
Support Level $96.03 $16.71
Resistance Level $119.25 $17.63
Average True Range (ATR) 4.64 0.36
MACD 0.24 0.03
Stochastic Oscillator 48.23 80.00

Price Performance

Historical Comparison
NICE
BLCO

About NICE NICE Ltd

Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: